Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.
Inozyme Pharma, a US-based developer of mineralisation disorder treatments, received $67m in series A2 funding yesterday from investors including pharmaceutical firms Novo and Sanofi, the latter through its Sanofi Ventures unit.
The round was co-led by Pivotal BioVenture Partners, the healthcare investment firm formed by property developer Nan Fung, and venture capital firm Sofinnova Investments.
Investment managers RA Capital Management and Cowen Healthcare Investments, hedge fund manager Rock Springs Capital and VC firms Longitude Capital and New Enterprise Associates (NEA)…
